ClinicalTrials.gg
RecruitingNCT07025070MINAUpdated Jun 17, 2025

The Link Between Physical Activity and Brain Health in Healthy Adults

An observational study in Alzheimer Disease, Inactivity and Preventive Therapy, sponsored by Technical University of Madrid. Recruiting at 1 site in Spain. Open to participants aged 40 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-17.

Sponsored by Technical University of Madrid · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2026, 10 months ago, but the record still lists the study as recruiting.
  • Started Nov 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
60
Ages
40 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 279 studies in Alzheimer Disease with a site in Spain — 54 open to participants now, 80 under way, 24 of them phase 3. Alzheimer Disease · Spain.

Planned enrollment
34th of 39
60 · median 400
Started
2024
with 19 others
Observational
39 of 279
15 open now
Primary completion
2026-01
later than 10 of 79 live
Registered
247th of 279
by date

Among the 279 studies in Alzheimer Disease with a site in Spain, this one is the 34th largest by planned enrollment of the 39 observational ones that give a count, is one of 20 that started in 2024, is one of 39 observational ones, reaches primary completion later than 10 of the 79 other live ones, and was the 247th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

54 of the 279 studies in Alzheimer Disease with a site in Spain are open now. Recruiting first, the newest first:

48 more — sign in →

All 54 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 40 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 279 studies in Alzheimer Disease with a site in Spain, or all of them as a file.
02

Study summary

The goal of this observational study is to investigate the cross-sectional relationship between physical activity and brain health from a multiscale approach (neuropsychology, neuroimaging, peripheral biomarkers and genetics) in former athletes and sedentary individuals. The main question it aims to answer is:

Do former athletes have better brain structure than sedentary people? Evaluating the differences in neurodegenerative processes between competitive training and sedentary and inactivity.

03

Conditions studied

  • Alzheimer Disease
  • Inactivity
  • Preventive Therapy

Keywords

  • physical activity
04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Region of Madrid

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Group A: ex-athletes and continue to perform regular physical exercise (minimum 3 days/week of moderate-vigorous intensity).
  • Group B: sedentary individuals, (i.e., perform \<150 min of moderate intensity exercise per week or IPAQ score\<600 MET min/week).
  • In both groups (A and B) the conditions of physical exercise or sedentary lifestyle must have been maintained for at least 6 months prior to the evaluations.
  • Not having a history of neurological or psychiatric disorder or suffering from a serious medical condition

Exclusion criteria

Exclusion Criteria:

  • Medical conditions that have a high risk of associated cognitive symptoms.
  • Severe head injury with loss of consciousness within the previous 5 years.
  • Alcoholism (>3 alcoholic drinks per day).
  • Chronic use of anxiolytics, neuroleptics, narcotics, anticonvulsants, or sedative hypnotics.
  • Hearing or visual impairment that would preclude testing
  • History of neurological disease with impact on cognition (e.g. cerebrovascular disease).
  • Incidental structural brain findings with impact on cognitive impairment or survival (e.g., malignant brain tumor).
  • Presence of severe systemic disease (e.g., cancer under treatment).
  • Consumption of anabolic substances.
  • Problems understanding spoken or written Spanish.
  • Those with pacemakers or metallic implants that may interfere with the MRI.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
60 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Ex-athletes and continue to exercise regularly
  • Sedentary individuals
06

What researchers measure

Primary outcomes

  1. Concentration of brain-derived neurotrophic factor (BDNF) in plasma (pg/mL)

    Measured with ELISA kit (e.g., R\&D Systems, Cat. #DY248). Higher BDNF reflects greater neurotrophic support.

    Time frame: Baseline

  2. Concentration of total tau protein in plasma (pg/mL)

    Assayed by high-sensitivity ELISA (e.g., Cusabio, Cat. #CSB-E13913h). Greater tau concentration indicates increased axonal injury or neurodegeneration.

    Time frame: Baseline

  3. Hippocampal volume measured by high-resolution 3 T T1-weighted MRI (mm³)

    Volume extracted with FreeSurfer; Larger values indicate greater hippocampal integrity

    Time frame: Baseline

  4. Resting-state functional connectivity between primary motor cortex and supplementary motor area measured by 3 T fMRI (Fisher-Z)

    Fisher-Z transformed correlation computed with CONN; Higher values indicate stronger connectivity

    Time frame: Baseline

  5. Digit Span Forward maximum span length (digits)

    Attention assessed with Wechsler Adult Intelligence Scale-IV Digit Span Forward subtest; Maximum correctly repeated digit sequence recorded. Higher scores indicate better attention/short-term memory capacity.

    Time frame: Baseline

  6. Trail Making Test Part A completion time (seconds)

    Visual attention and processing speed measured by TMT-A; time to connect 25 numbers in ascending order recorded. Shorter times indicate better performance.

    Time frame: Baseline

  7. Digit Span Backward maximum span length (digits)

    Working memory measured with WAIS-IV Digit Span Backward; Longest correctly repeated backward sequence recorded. Higher scores indicate better working memory.

    Time frame: Baseline

  8. Trail Making Test Part B completion time (seconds)

    Executive function (set-shifting) assessed by TMT-B; Time to alternately connect numbers and letters recorded. Shorter times indicate better executive control.

    Time frame: Baseline

  9. Verbal fluency (F-A-S) total words in 60 s (count)

    Phonemic fluency tested with Controlled Oral Word Association Test (letters F, A, S, 60 s each); total correct words across three letters. Higher counts indicate better executive retrieval fluency.

    Time frame: Baseline

  10. Stroop Color-Word interference score (seconds)

    Inhibition assessed with Golden Stroop test; The count of completions within 45 seconds is recorded. Lower times reflect better inhibitory control.

    Time frame: Baseline

  11. Montreal Cognitive Assessment (MoCA) total score (0 - 30 points)

    10-minute screening of global cognition covering memory, attention, language, visuospatial, and executive domains. Values ≥ 26 are considered normal. Higher scores indicate better cognition.

    Time frame: Baseline

  12. Number of participants carrying at least one APOE ε4 allele (count of participants)

    Genomic DNA isolated from EDTA whole blood; APOE genotyping by TaqMan SNP assays rs429358 and rs7412. Any ε4-containing genotype (ε2/ε4, ε3/ε4, ε4/ε4) classified as "ε4 carrier". Higher counts = higher ε4 prevalence.

    Time frame: Baseline

Secondary outcomes

  1. Maximal oxygen uptake (VO₂max) measured by CPET with ramp protocol on treadmill (mL·kg-¹·min-¹)

    Cardiopulmonary exercise test performed on treadmill using Ramp incremental ramp. Breath-by-breath gas exchange collected via metabolic cart. VO₂max defined as the highest 30-s average during the test; Higher values indicate better cardiorespiratory fitness.

    Time frame: Baseline

  2. Mean daily minutes of moderate-to-vigorous physical activity measured by ActiGraph wGT3X-BT accelerometer over 7 days (min/day)

    Device worn on non-dominant wrist 24 h/day for 7 consecutive days. Raw data (100 Hz) processed in ActiLife with 10 s epochs; Freedson adult cut-points ≥ 1 952 counts·min-¹ define MVPA. Higher values indicate greater physical activity.

    Time frame: Baseline

  3. Body mass index (BMI) calculated from weight and stadiometer-measured height (kg/m²)

    Height measured to 0.1 cm with height measuring rod. Weight obtained from InBody system. BMI = weight ÷ height². Higher BMI indicates greater overall adiposity.

    Time frame: Baseline

  4. Peak force of mid-thigh-pull test measured by portable force dynamometer (N)

    Participants perform two maximal isometric mid-thigh pulls on calibrated dynamometer with 60 s rest. The higher of two trials recorded as peak force. Greater values indicate stronger lower-limb strength.

    Time frame: Baseline

  5. Handgrip strength measured by grip dynamometer (kg)

    Standing posture, shoulder neutral, elbow extended. Two maximal squeezes per hand with dynamometer; 30 s rest between trials. Best value used for analysis. Higher values reflect greater grip strength.

    Time frame: Baseline

  6. Timed Up-and-Go (TUG) test completion time (seconds)

    Participants stand up from a 45-cm chair, walk 3 m, turn, return, and sit; time recorded by timers. Two trials with 1 min rest; Shorter time retained. Lower times represent better agility.

    Time frame: Baseline

  7. Balance stability and speed score measured by TANITA force platform (unitless)

    Balance and speed assessed on TANITA analyzer in eyes-open seated posture; Stand-up as fast as possible when signaled, repeat 3 times to get an optimal value; Manufacturer's composite stability index automatically computed (range 0-100). One 30-s trial; higher scores denote better balance.

    Time frame: Baseline

  8. Percentage body fat measured by multifrequency bioimpedance analyzer InBody system (%)

    Participants barefoot, InBody 770 provides whole-body fat percentage derived from segmental impedance; Higher values denote greater adiposity.

    Time frame: Baseline

  9. Skeletal muscle mass measured by multifrequency bioimpedance analyzer InBody system (kg)

    Analyzer outputs total skeletal muscle mass. Greater values indicate higher muscularity.

    Time frame: Baseline

  10. Waist circumference measured by flexible tape at midpoint between lowest rib and iliac crest (cm)

    Measured at end-expiration; two readings within 1 cm averaged. Larger values indicate central adiposity.

    Time frame: Baseline

  11. Hip circumference measured by flexible tape at level of greater trochanters (cm)

    Two readings averaged; used with waist girth to compute waist-to-hip ratio.

    Time frame: Baseline

  12. Serum triglycerides measured by enzymatic colorimetric assay (mg/dL)

    Fasting venous blood; triglycerides quantified on chemistry analyzer with glycerol phosphate oxidase method. Higher values indicate greater dyslipidemia risk.

    Time frame: Baseline

  13. Serum total cholesterol measured by enzymatic colorimetric assay (mg/dL)

    Chemistry analyzer; Cholesterol esterase/oxidase method. Higher levels indicate increased cardiovascular risk.

    Time frame: Baseline

  14. Serum high-density lipoprotein (HDL) cholesterol measured by enzymatic assay (mg/dL)

    Selective detergent method. Higher HDL is considered protective.

    Time frame: Baseline

  15. Serum low-density lipoprotein (LDL) cholesterol calculated by Friedewald formula (mg/dL)

    LDL-C = total-C - HDL-C - (triglycerides ÷ 5). Higher LDL indicates greater atherogenic risk.

    Time frame: Baseline

  16. Serum 25-hydroxyvitamin D concentration measured by chemiluminescent immunoassay (ng/mL)

    Serum 25-hydroxyvitamin D concentration measured by chemiluminescent immunoassay (ng/mL)

    Time frame: Baseline

  17. Mean daily sedentary time measured by ActiGraph wGT3X-BT accelerometer over 7 days (min/day)

    Sedentary time defined as \< 100 counts·min-¹ in vector-magnitudes; summed across valid waking wear days (≥ 10 h/day). Larger values denote more sedentary lifestyle.

    Time frame: Baseline

  18. Mean nightly sleep duration measured by ActiGraph wGT3X-BT over 7 nights (hours/night)

    Sleep/wake scored with Cole-Kripke algorithm; average total sleep time across nights with ≥ 160 min valid sleep. Longer duration indicates better sleep quantity.

    Time frame: Baseline

  19. Total physical activity measured by International Physical Activity Questionnaire - Long Form (MET·min/week)

    Four IPAQ domains are summed; for each activity, minutes are multiplied by the corresponding MET value and then summed. Higher values indicate greater total energy expenditure.

    Time frame: Baseline

  20. Mediterranean Diet Adherence Score measured by 14-item Mediterranean Diet Adherence Screener (0 - 14 points)

    Each of the 14 items is scored 0 or 1 and summed (total 0-14). A score ≥ 9 is considered high adherence. Higher scores indicate greater adherence to the Mediterranean dietary pattern.

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
  • Faculty of Physical Activity and Sports Sciences (INEF)
    Madrid, 28040, Spain
    Recruiting
08

References and documents

Related links

Individual participant data

Plan to share: Undecided — At this stage, the investigators have not yet decided whether our IPD will be shared. Data sharing policies and procedures are still under discussion within our research group and institution. Further consideration will be given to ethical requirements, participant privacy, and potential future analyses before making a final decision.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2024 (actual). Primary completion is estimated for Jan 2026, 14 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2025
First posted
Jun 17, 2025
StartActual
Nov 25, 2024
Primary completionEst.
Jan 2026
CompletionEst.
Sep 2026
Last update
Jun 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07025070
Lead sponsor
Technical University of Madrid
Responsible party
Songxin Tang (Principal Investigator, Technical University of Madrid) — Principal investigator
First posted
Jun 17, 2025
Start date
Nov 25, 2024
Primary completion
Jan 2026 (estimated)
Completion
Sep 2026 (estimated)
Last update
Jun 17, 2025

Study contacts

Songxin Tang
Contact
songxin.tang@alumnos.upm.es
+34 663002621

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion